BCR-ABL tyrosine kinase inhibitors

A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes.

BCR-ABL tyrosine kinase inhibitors inhibit the enzyme BCR-ABL tyrosine kinase, which is important in the pathogenesis of chronic myelogenous leukemia (CML).

Chronic myelogenous leukemia occurs due a single genetic abnormality, known as the Philadelphia chromosome. During the translocation when the Philadelphia chromosome is created, a fusion gene called BCR-ABL gene is formed. The BCR-ABL gene encodes for the BCR-ABL tyrosine kinase. The BCR-ABL positive cells in chronic myelogenous leukemia have increased proliferation and resistance to cell death.

BCR-ABL tyrosine kinase inhibitors are used to treat chronic myelogenous leukemia.

See also

Medical conditions associated with BCR-ABL tyrosine kinase inhibitors:

• Acute Lymphoblastic Leukemia
• Chronic Eosinophilic Leukemia
• Chronic Myelogenous Leukemia
• Dermatofibrosarcoma Protuberans
• Gastrointestinal Stromal Tumor
• Hypereosinophilic Syndrome
• Leukemia
• Myelodysplastic Diseases
• Myeloproliferative Disorders
• Systemic Mastocytosis

Drug List:

Sprycel

Gleevec

Tasigna